Walleye Capital
BBIO icon

Walleye Capital’s BridgeBio Pharma BBIO Stock Holding History

Walleye Capital’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$114K Sell
1,535
-227,058
-99% -$15.9M ﹤0.01% 3830
2026
Q1 		$17M Buy
228,593
+223,753
+4,623% +$16.2M 0.07% 236
2025
Q4 		$370K Sell
4,840
-1,944
-29% -$128K ﹤0.01% 3148
2025
Q3 		$352K Sell
6,784
-14,912
-69% -$727K ﹤0.01% 2881
2025
Q2 		$937K Buy
21,696
+5,347
+33% +$194K ﹤0.01% 2105
2025
Q1 		$565K Buy
16,349
+6,521
+66% +$220K ﹤0.01% 2450
2024
Q4 		$270K Buy
+9,828
New +$254K ﹤0.01% 3520
2024
Q3 		– Sell
-77,613
Closed -$2.04M – 5293
2024
Q2 		$1.97M Buy
77,613
+55,705
+254% +$1.52M ﹤0.01% 2121
2024
Q1 		$677K Buy
+21,908
New +$745K ﹤0.01% 2947
2023
Q4 		– Sell
-51,872
Closed -$1.37M – 4933
2023
Q3 		$1.37M Buy
51,872
+19,047
+58% +$541K ﹤0.01% 2013
2023
Q2 		$565K Buy
+32,825
New +$494K ﹤0.01% 2347
2022
Q1 		– Sell
-52,953
Closed -$883K – 2289
2021
Q4 		$883K Buy
+52,953
New +$2.24M 0.03% 666
2021
Q2 		– Sell
-4,156
Closed -$256K – 1342
2021
Q1 		$256K Buy
+4,156
New +$272K 0.01% 829

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Walleye Capital's BBIO Position: Q2 2026 in Review

Walleye Capital reduced its BridgeBio Pharma (BBIO) stake by 99% in Q2 2026, selling an estimated $15.9M and leaving 1,535 shares worth $114K. The position accounts for ﹤0.01% of the portfolio, ranked #3830.

Walleye Capital first reported a position in BBIO in Q1 2021 and has held it in 13 quarters since. The position peaked at $17M in Q1 2026. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Walleye Capital held 1,535 shares of BridgeBio Pharma worth $114K as of Q2 2026.
  • Walleye Capital sold 227,058 BridgeBio Pharma shares in Q2 2026, an estimated $15.9M.
  • BridgeBio Pharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3830 holding.
  • Walleye Capital first reported a position in BridgeBio Pharma in Q1 2021 and has held it in 13 quarters since.
  • Walleye Capital's BridgeBio Pharma position peaked at $17M in Q1 2026.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.